#7

PATENT Docket No. 23647-20007.20 Client Ref. bak

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on 1995.

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFF.

In the application of:

MICHAEL C. KIEFER et al.

Serial No.:

08/320,157

Filing Date:

07 October 1994

For

NOVEL APOPTOSIS-

MODULATING PROTEINS, DNA ENCODING THE PROTEINS AND METHODS OF USE

THEREOF

Examiner: Unassigned

Group Art Unit: 4806

RECEIVED

GROUP 1800

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In addition to the Information Disclosure Statement Under 37 C.F.R. § 1.97 mailed to the PTO on March 23, 1995, the citations on the attached sheet, copies attached, may also be material to the examination of the above-identified application and are, therefore, submitted in compliance with the duty of disclosure as defined in 37 C.F.R. § 1.56. The Examiner is requested to make these citations of record in the application.

International (PCT) Patent Publication No. WO 95/05750 (03/02/95).

Chittenden et al., "Induction of apoptosis by the Bcl-2 homologue Bak" *Nature* (1995) 347:733-736.

Farrow et al., "Cloning of a *bcl-2* homologue by interaction with adenovirus E1B 19K" *Nature* (1995) *374*:731-733.

Kiefer et al., "Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak" *Nature* (1995) *374*:736-739.

This Supplemental Information Disclosure Statement is submitted before receipt of the first Office Action on the merits. Accordingly, the applicants believe that no fee is due. However, the Commissioner is hereby authorized to charge any fees that may be required by this paper to Deposit Account No. 03-1952.

Applicants would appreciate the Examiner's initialing and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.

This Supplemental Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information,

protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Dated: <u>"/7</u>, 1995

Respectfully submitted,

Registration No. 33,943

Morrison & Foerster

755 Page Mill Road Palo Alto, California 94304-1018

Telephone: (415) 813-5695 Facsimile: (415) 494-0792